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Abstract
Introduction: Changes in bone mineral density (BMD) in the hand as evaluated by digital X-ray radiogrammetry
(DXR) of the second to fourth metacarpal bones has been suggested to predict future joint damage in patients
with rheumatoid arthritis (RA). This study’s objective was to investigate whether DXR-BMD loss early in the course
of the disease predicts the development of joint damage in RA patients followed for up to 20 years.
Methods: A total of 183 patients (115 women and 68 men) with early RA (mean disease duration, 11 months)
included from 1985 to 1989 were followed prospectively (the Lund early RA cohort). Clinical and functional
measures were assessed yearly. Joint damage was evaluated according to the Larsen score on radiographs of the
hands and feet obtained in years 0 to 5 and years 10, 15 and 20. These radiographs were digitized, and BMD of
the second to fourth metacarpal bones was evaluated by DXR. Early DXR-BMD change rate (that is, bone loss) per
year calculated from the first two radiographs obtained on average 9 months apart (SD ± 4.8) were available for
135 patients. Mean values of the right and left hand were used.
Results: Mean early DXR-BMD loss during the first year calculated was -0.023 g/cm
2 (SD ± 0.025). Patients with
marked bone loss, that is, early DXR-BMD loss above the median for the group, had significantly worse progression
of joint damage at all examinations during the 20-year period.
Conclusions: Early DXR-BMD progression rate predicted the development of joint damage evaluated according to
Larsen score at year 1 and for up to 20 years in this cohort of early RA patients.
Introduction
Rheumatoid arthritis (RA) is an inflammatory disease
characterized by chronic synovial inflammation com-
monly associated with destruction in cartilage and bone
tissue. Changes in bone metabolism during the course of
RA are usually divided into periarticular bone loss with
or without focal articular bone erosion and generalized
osteopenia manifested by loss of both trabecular and cor-
tical bone. Periarticular bone loss occurs early and often
before erosion is apparent. This is linked to the inflam-
matory process and may be driven by locally released
inflammatory mediators such as the receptor activator of
nuclear factor (NF)-B and its ligand RANKL and the
decoy receptor of RANKL, osteoprotegerin. These find-
ings have been extensively investigated and reviewed
[1-9]. In RA, periarticular bone loss is seen predomi-
nantly in the hands and feet, which are affected early in
t h ed i s e a s ec o u r s e .T h u s ,b o n el o s sm a yb eam a r k e ro f
disease activity, and it has been suggested that it may also
relate to future joint damage [4,5,8].
E a r l yl o s so fb o n em i n e r a ld e n s i t y( B M D )i nt h eh a n d
has been shown to covariate with radiographic joint
damage as measured by the Sharp-van der Heide (SvdH)
or Larsen score in RA patients [4-11]. However, outcome
measures do not necessarily agree. The two more estab-
lished radiological scores in RA, the Larsen and the
SvdH, demonstrate only a modest correlation. This may
partly be explained by the fact that the Larsen score is
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regions [12-14].
The bone mineral density measured by digital X-ray
radiogrammetry (DXR-BMD) determination has the
advantage of being well standardized and not subject to
the interpretation and measurement errors that are
inherent in both the Larsen and the SvdH scoring sys-
tems. Furthermore, DXR-BMD is reliable in quantifying
demineralization and/or osteoporosis, which have been
shown to be only imprecisely verified with conventional
radiography. The radiographic scoring methods and
DXR-BMD can be performed on historical radiographs,
provided that these are of sufficient quality and taken in
a standardized fashion. This is in contrast to other
methods of BMD measurements such as ultrasound,
dual-emission X-ray absorptiometry and peripheral
quantitative computed tomography, all of which have as
a focus the measurement of BMD, are not retrospectively
applicable to standard radiographs of the hands and
sometimes focus on generalized osteopenia [6-8,15-18].
In Lund, Sweden, we have prospectively monitored a
cohort of early RA patients since 1985 and have more
than 20 years of follow-up inf o r m a t i o no nr a d i o g r a p h i c
and clinical outcomes [19,20]. In the present study, we
have examined the relationship between early DXR-BMD
changes and short- and long-term outcomes as measured
radiographically by the Larsen score of the hands and
feet. Furthermore, we have examined the relationship
between baseline BMD, Larsen score and early Larsen
progression and long-term radiographic outcome.
Materials and methods
Patients
A total of 183 patients (115 women and 68 men) with
early definite RA who had a mean symptom duration of
11 months (SD ± 7; range, 0 to 24 months) included
between 1985 and 1989 were followed prospectively (the
Lund early RA cohort). Clinical and functional measures
were assessed, as previously reported, at least once yearly
[19]. The validated Swedish version of the Health Assess-
ment Questionnaire (HAQ), which includes the use of
aids, was used [21]. Approval from the Ethical Review
Board at Lund University (LU 525-02) and informed con-
sent from each patient were obtained for this study.
Throughout the study all patients with active disease
were offered treatment with disease-modifying antirheu-
matic drugs (DMARDs) according to current clinical
practice. About 50% of patients from the original cohort
started treatment with DMARDs within 1 year after diag-
nosis. D-penicillamine and antimalarial drugs were most
commonly used in the early years, and methotrexate
became most frequently used during the 1990s.
In total, 48 patients from the original cohort were
excluded from the analysis. In three cases, only hand
and no feet radiographs were available as the first radio-
graphs; in eight cases, the first DXR measurements were
made on prediagnosis inclusion radiographs which were
not Larsen scored; and in an additional 37 patients,
radiographs were taken using a magnifying analogous
technique precluding DXR measurements. There were
no statistically significant differences regarding patient
characteristics between included and excluded patients.
DXR was developed as a computerized method of radio-
grammetry to measure cortical bone thickness in diaphysis
of the second to fourth metacarpal bones using standard
hand radiographs. Thus, DXR-BMD quantifies only the
cortical bone tissue where the bone metabolism is minor
compared to trabecular bone tissue [9]. The method has
been described in more detail elsewhere [9,15-17]. Briefly,
t h ee a r l yD X R - B M Dc h a n g er a t e( b o n el o s s )p e ry e a r ,
expressed in grams per square centimeter, was calculated
on the basis of the first two available conventional radio-
graphs of the hands. Exact dates of the radiographs were
used to calculate the yearly change rate. The same radio-
graphs were used for both radiographic scoring and mea-
surement of hand bone density. The radiographs were
digitized to 300 dpi, 12-bit gray scale format with DICOM
software using a Vidar Diagnostic Pro Plus digitizer
(VIDAR Systems Corp., Herndon, VA, USA), and the
resulting digital radiographs were analyzed using dxr-
online software (Sectra, Linköping, Sweden). The dxr-
online software recognizes regions of interest around the
narrowest part of the second, third and fourth metacarpal
bone diaphysis and automatically measures the BMD
through a combination of radiogrammetry and textural
analysis. Mean values of the right and left hand were used.
The smallest detectable difference in elevated early DXR-
BMD loss has been shown to be 0.0048 g/cm
2 [7].
Larsen score
Joint damage was evaluated on radiographs of the hands
and feet according to the Larsen method as described
previously [13]. In short, 32 joints in the hands and feet
were evaluated. Each joint was compared to a standard
reference film, and changes were graded from 0 to 5,
with 0 being normal; 1 being joint space narrowing, soft
tissue swelling or periarticular osteoporosis; and 2 to 5
representing a progressively increasing degree of erosion
and destruction. A joint damage score was calculated by
adding all scores, with the scores for joints in the wrists
multiplied by 5, resulting in a range of 0 to 200. Radio-
graphs were obtained at inclusion in the study as well as
after 1, 2, 3, 4, 5, 10, 15 and 20 years. Early progression
of Larsen scores per year was measured as the difference
between the first two available sets of both hand and
feet radiograms using the exact dates of the radiograms
to calculate the progression rate per year (Larsen units/
year).
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Early DXR-BMD changes stratified according to the med-
ian and upper and lower halves were compared to each
other. No imputation of missing data was performed. Dif-
ferences between the groups were calculated using the c
2
test for ordinal variables and the Mann-Whitney U test for
numerical variables. Influences of age and sex on baseline
BMD, early DXR-BMD change and baseline Larsen score
were estimated by performing analysis of covariance
(ANCOVA). To maximize statistical power, differences
between Larsen scores at 10 years were analyzed using a
generalized linear regression model adjusted for age, sex
and baseline values of the variable tested. This was done
because 69 patients died during follow-up (the majority
after 10 years), and thus only contributed information for
a more limited follow-up period. Correlations were calcu-
lated using Spearman’s rank correlation coefficient. Values
are given as means with 95% confidence intervals (95%
CIs) unless stated otherwise. A P value < 0.05 was consid-
ered statistically significant.
Results
Patients and characteristics according to early BMD-DXR
Complete data were available for 135 patients. Mean (±
SD) DXR-BMD at baseline was 0.593 ± 0.08 g/cm
2. Mean
(± SD) DXR-BMD progression rate (bone loss), defined as
change in DXR-BMD between the first two existing radio-
graphs was -0.023 g/cm
2 ± 0.025.
Patient characteristics stratified according to the med-
ian value (-0.019) of early DXR-BMD loss are presented
in Table 1. This stratification identified several differ-
ences in baseline variables. Patients with high bone loss
were older, had longer symptom duration at diagnosis
and had higher erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), HAQ scores and Disease Activity
Score using 44 joint counts (DAS44), while sex and Lar-
sen score were not significantly different. ANCOVA
showed that older patients had both significantly lower
baseline BMD (P < 0.001) and higher early DXR-BMD
changes (P < 0.001), while females only had lower base-
line BMD (P < 0.001), but not significantly higher early
DXR-BMD changes (P = 0.690).
Early DXR-BMD association with and prediction of Larsen
score
On the basis of univariate linear regression analysis,
early bone loss was significantly associated with higher
Larsen score at year 10 as were ESR and CRP levels,
HAQ score and Larsen score at baseline. ANCOVA
showed that the adjusted 10-year Larsen score in the
group with high early bone loss (mean, 95% CI) was
30.2 (95% CI, 15.7 to 44.7) above the group with low
early bone loss (P < 0.001).
In multivariate regression analysis, high early DXR-
BMD loss (patients with early bone loss levels above the
median), baseline Larsen scores and ESR levels remained
predictive for the Larsen score at year 10 (Table 2). In
patients with erosive disease at baseline (that is, Larsen
score at baseline ≥2) who had early DXR-BMD, the
median value was still associated with a higher Larsen
score at 10-year follow-up (P = 0.031). Very few patients
(n = 2) in this cohort had already been treated with pre-
dnisolone at RA diagnosis (baseline), and therefore this
variable was not entered into the regression model.
Larsen scores at years 0, 1, 3, 4, 5, 10, 15 and 20 strati-
fied according to the median of early DXR-BMD loss are
given in Figure 1. There is a diverging trend during the
whole follow-up period, which is most marked in the
first 5 years. The increase in 95% CI at the later time
points illustrates the increasing number of deceased
patients. When using the smallest detectable difference,
0.0048 g/cm
2/year [7], as a cutoff for elevated early DXR-
BMD loss, a total of 97 patients (72%) were in the higher
bone loss group, while 38 patients (28%) were in the
lower bone loss group. Plotting the patients with early
bone loss >0.0048 compared to those with lower early
bone loss yielded results similar to those of median strati-
fication (data not shown). During the first 5 years, the
Larsen score deteriorated at a faster pace in patients with
elevated early bone loss. However at time points 10, 15
and 20 years, these differences were not significant
between the groups. The Spearman correlations between
early bone loss and Larsen scores at years 1, 2, 3, 4, 5, 10
and 20 were all significant, with Spearman’s r values
between 0.359 and 0.223.
Comparing DXR-BMD for Larsen scores for hands and
feet
When looking at Larsen scores for hands and feet sepa-
rately, the clear differences between groups stratified
according to early DXR-BMD loss remained for the
hands. For the Larsen scores of the feet, the picture was
similar, with the group with high early DXR-BMD loss
always having higher mean Larsen scores, but at most
time points the differences were nonsignificant (data not
shown).
DXR-BMD progression rate over time
To study the progression rate of DXR-BMD loss over
time, we calculated the data for the yearly progression
rates between time points 0 and 1, 2, 3 and 4 years,
which were (means and 95% CIs): 2.2 (1.3 to 3.0), 2.2
(1.5 to 2.9), 2.7 (2.0 to 3.3) and 2.3 (1.8 to 2.8), respec-
tively. There was an overall trend of decreasing DXR-
BMD progression rate over time, but the limited
number of patients precludes firm statistical confirmation.
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on later Larsen scores
After stratifying for the median of early changes in
Larsen scores, a very similar picture to that observed for
early DXR-BMD changes was found (Figure 2). Also,
here there is a diverging trend during the whole follow-
up period, and ANCOVA showed that the adjusted
10-year Larsen scores (95% CI) in the group with more
elevated early Larsen score progression was 32.3 (20.6 to
44.0) above the group with low early Larsen score pro-
gression. The association between early Larsen score
changes with 10-year Larsen scores was 0.540 (Spear-
man’s r).
Baseline BMD or Larsen scores and late Larsen scores
Median stratification of baseline BMD or Larsen score
did not identify any trends of predictability for long-
term radiological progression as measured by the Larsen
score (Figures 3 and 4). The Spearman’s r correlation
between 10-year Larsen score and baseline BMD was
-0.056, and between 10-year Larsen score and baseline
Larsen score it was 0.199.
Discussion
In the present report, we have demonstrated that early
bone mineral loss in the hands of patients with RA pre-
dict joint damage as measured by the radiographic Lar-
sen score over a 20-year observation period. The
difference was seen as early as 1 year after baseline all
the way to 20-year follow-up.
We could not verify that DXR-BMD loss is more
marked in the early phase of the disease, which has
been reported by others, but our study had more limited
power [4-11]. Overall our results are consistent with
those of other studies. A longitudinal observational
study including early RA patients with disease duration
<1 year showed that changes in DXR-BMD of the sec-
ond to fourth metacarpal bones at year 1 were specific
and sensitive in identifying both patients who developed
erosions scored using both the Larsen and SvdH meth-
ods and those whose existing erosion had progressed at
Table 1 Patient characteristics at diagnosis stratified according to the median of the early DXR-BMD loss
a
High bone loss Low bone loss
(higher than median) (less than median) P value
Patient characteristics (n = 69) (n = 66)
Baseline characteristics
Mean age, yr (± SD) 57.7 (11.4) 46.4 (11.4) <0.001
Mean symptom duration at inclusion, months (± SD) 10.6 (6.8) 13.0 (7.1) 0.035
Mean HAQ, 0 to 3 (± SD) 1.0 (0.6) 0.7 (0.6) 0.004
Mean DAS44, 0 to 10 (± SD) 3.5 (1.1) 3.0 (1.0) 0.024
Mean CRP, mg/l (± SD) 34 (36) 18 (31) <0.001
Mean ESR, mm/1 hour (± SD) 46 (30) 28 (25) <0.001
Female, % 62% 67% ns
RF-positive, % 81% 85% ns
ACPA-positive, % 78% 74% ns
Smoker, % 34% 32% ns
Mean Larsen score, 0 to 200 (± SD) 10.2 (9.4) 6.6 (6.2) 0.100
Mean BMD, g/cm
2 (± SD) 0.57 (0.09) 0.62 (0.07) <0.001
Early DXR-BMD loss, g/cm
2 (± SD) -0.0418 (0.02) -0.0034 (0.008) <0.001
Early DXR-BMD loss, % -7.6 -0.57 <0.001
Treatment during total observation period, %
DMARDs ever, % 80% 71% ns
MTX ever, % 39% 42% ns
Prednisolone ever, % 48% 47% ns
aSD, standard deviation; DXR-BMD, bone mineral density (BMD) measured by digital X-ray radiogrammetry; HAQ, Health Assessment Questionnaire; DAS44, Disease
Activity Score using 44 joint counts; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anticitrullinated peptide antibodies;
DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; ns, not significant. Medication refers to treatment for the whole observation period.
Table 2 Impact of high early DXR-BMD loss and baseline
demographic and disease characteristics on Larsen score
at year 10 (linear regression model)
a
Patient demographics and disease characteristics B P_value
Early bone loss above median (yes/no) 16.572 0.037
Sex 3.573 0.620
Age -0.462 0.134
ESR 0.540 0.000
Larsen score at baseline, 0 to 200 0.807 0.068
ACPA (yes or no) -1.371 0.862
aB, the estimated regression coefficient; ESR, erythrocyte sedimentation rate;
ACPA, anticitrullinated peptide antibodies; high early DXR-BMD loss is defined
as bone loss above median value.
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tion up to 4 years, hand bone loss measured by DXR-
BMD at year 1 was predictive of subsequent radio-
g r a p h i cd a m a g es c o r e db yt h eS v d Hm e t h o da t5a n d
10 years [7].
We did not attempt to study the implication of late
D X R - B M Dl o s si nt h i ss t u d y ,s i n c ew ea i m e dt of i n d
early predictors of outcome. On the other hand, the
clinical value of early bone mineral loss as a predictor of
future joint damage as measured by Larsen score should
not be overemphasized. The relationship is well vali-
dated on the group level, but cannot be recommended
for use as the only predictor as illustrated by the rela-
tively low correlations. On the other hand, early pro-
gression in Larsen score also shows a clear predictive
value for later joint damage, but the low correlations
revealed that this information also must be confined to
the group level. Early bone loss is a risk factor, in addi-
tion to other known risk factors. Thus, although statisti-
cally significant predictive value for RA prognosis can
be found for several early findings such as the presence
of rheumatoid factor, anticyclic citrullinated peptide
antibody, elevated ESR level and cartilage oligomeric
matrix protein level, their value in clinical decisions
regarding treatment of the individual patient must not
be overemphasized [22-29]. Treatment decisions rely
heavily on several aspects not covered by conventional
predictive analyses, such as perceived pain, working
situation, deteriorating function and so on.
The findings that early DXR-BMD loss in the cortical
shaft of metacarpal bones is predictive of later progres-
sion of joint-related hand Larsen score was not unex-
pected because of the close vicinity of these structures.
We were not able to demonstrate an unequivocal rela-
tionship between early DXR-BMD loss in the metacarpal
bones and Larsen score in the foot, even though there
was a quite clear trend for such a relationship as has
been reported for SvdH [11]. However, in the Larsen
scoring system, as in the SvdH scoring system, the feet
do not have the same number of joints as the hands,
thus giving a ceiling effect with reduced possibility of
finding differences [12-14]. This could at least partly
explain the nonsignificant differences found in the
Larsen scores of the feet. Methods of using DXR-BMD
have not been developed for the metatarsal bones, thus
precluding direct comparisons of hand and foot bone
Figure 1 Radiological Larsen score progression over time after stratification according to the median (-0.0185 g/cm
2 per year) of early
bone mineral density measured by digital X-ray radiogrammetry (DXR-BMD) change. High loss (black solid line) versus low loss (red
dotted line) of DXR-BMD. Values are given as means with 95% confidence intervals (95% CIs). The larger 95% CIs at 15 and 20 years illustrate the
decreasing number of patients at these time points.
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eralized bone loss and multiple joint damage as mea-
sured by the total Larsen score.
Several factors are known to promote osteopenia, such
as female sex, older age and severe RA [30,31]. It was
therefore not unexpected to find that the degree of early
DXR-BMD loss identified patients with different base-
line characteristics. Thus early markers of more severe
disease, such as high HAQ score, high DAS44 score and
high ESR and CRP levels, were all more common
among the patients with higher DXR-BMD loss. Also
older age contributed to high early bone loss, while
rheumatoid factor status or anticitrullinated peptide
antibody positivity and sex did not. The low numbers of
patients taking systemic glucocorticoids represent the
therapeutic tradition in the 1980s and prevent any
meaningful analysis of this cause of osteopenia.
The strength of the DXR-BMD technique is that it is
well standardized, can be used to perform a large num-
ber of objective measurements and can be done on
existing radiographs. However, the radiographs must be
t a k e ni nas t a n d a r d i z e df a s h i o ni ft h er e s u l t sa r et ob e
given in grams per square centimeter. DXR-BMD can
be somewhat more generalizable if the results are given
as percentages, which are sufficient to measure relative
changes. Both the Larsen and SvdH scores require
experienced and licensed readers and still have a sizable
reading error [12], a shortcoming that DXR-BMD has
minimized, although the radiographic equipment used
can influence the results to a minor degree. DXR-BMD
is able to quantify only cortical and not trabecular bone
mass, thus limiting its use as a general osteopenia mea-
sure. However, periarticular cortical bone loss, in some
cases measured by DXR-BMD, has been shown to pre-
dict erosive disease in RA [4-11].
The strengths of the current study include its commu-
nity-based recruitment, its prospective gathering of a
large amount of laboratory and clinical information and
its almost complete follow-up. The exclusion of the siz-
able proportion of RA patients who died during follow-
up could be argued for. However, they did represent a
group of RA patients that presumably had several sever-
ity markers in common, and the exclusion of these
patients could seriously hamper the results of the study.
We also refrained from extrapolating and imputing
missing Larsen scores, since this also leads to several
Figure 2 Radiological Larsen score progression over time after stratification according to the median (5.5 units) of early change in
Larsen score. High (black solid line) versus low (red dotted line) early ΔLarsen scores. Values are given as means with 95% confidence intervals
(95% CIs). The larger 95% CIs at 15 and 20 years illustrate the decreasing number of patients at these time points.
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2) baseline BMD. High BMD
(black solid line) versus low BMD (red dotted line) values at baseline are shown.
Figure 4 Radiological Larsen score progression over time after stratification according to median (5.5 units) of baseline Larsen score.
High Larsen score (black solid line) versus low Larsen score (red dotted line) at baseline is shown.
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size.
The limitations of the present study include the retro-
spective approach of DXR-BMD measurements on pre-
existing radiographs. This accounted for the loss of 48
patients. However, their baseline characteristics were
largely similar to those of the total group of patients.
Also, the total sample size was not very large, but this
was one of the very first early RA cohorts recruited, and
it represents what one center could bear during a total
of >25 years of follow-up. Thus, although some of the
finer details may not always be statistically verified, the
cohort size permits firm conclusions on several robust
sets of data such as those in the present report. It must
be remembered that in comparing data with more
recent early RA studies, in which new and often more
liberal criteria sets are being used, we used the 1958
American Rheumatism Association criteria to establish
definite diagnoses of RA in the present study [32]. Also,
the introduction of new and potentially bone loss-pro-
tective treatment cohorts must be accounted for in
more recent early RA studies when comparing them
with the Lund early RA cohort treated according to the
clinical standards used over 25 years ago.
Conclusions
Early DXR-BMD loss in the present study predicted
future joint damage as measured by Larsen score both
in the short-term perspective (1 year), which confirms
previous studies that used the SvdH score, and for the
first time in the very long-term perspective (20 years).
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